Increased Beta2-Adrenoceptors in Doxorubicin-Induced Cardiomyopathy in Rat

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Merlet, Nolwenn ^a,b   Piriou, Nicolas ^a   Rozec, Bertrand ^a,c   Grabherr, Amandine ^a   Lauzier, Benjamin ^a,b   Trochu, Jean Noël ^a,b   Gauthier, Chantal ^a,b  

^a L INSTITUT DU THORAX   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; DOXORUBICIN; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; PERTUSSIS TOXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; DIASTOLIC DYSFUNCTION; DOPPLER ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; HEART CATHETERIZATION; HEART FUNCTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; MALE; MORTALITY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SYSTOLIC DYSFUNCTION; WESTERN BLOTTING;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CARDIOMYOPATHIES; CARDIOTONIC AGENTS; COLFORSIN; DOXORUBICIN; GENE EXPRESSION REGULATION; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; HEART; ISOPROTERENOL; MALE; MYOCARDIAL CONTRACTION; PERTUSSIS TOXIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, ADRENERGIC, BETA-3; SURVIVAL ANALYSIS;

RATTUS;

EID: 84878575760     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064711     Document Type: Article

References (55)

1. Connors JM, (2005) State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol 23: 6400-6408.
2. Grimer R, Judson I, Peake D, Seddon B, (2010) Guidelines for the management of soft tissue sarcomas. Sarcoma 2010: 506182.
3. Ferreira AL, Matsubara LS, Matsubara BB, (2008) Anthracycline-induced cardiotoxicity. Cardiovasc Hematol Agents Med Chem 6: 278-281.
4. Nakamura T, Ueda Y, Juan Y, Katsuda S, Takahashi H, et al. (2000) Fas-mediated apoptosis in adriamycin-induced cardiomyopathy in rats: In vivo study. Circulation 102: 572-578.
5. Ueno M, Kakinuma Y, Yuhki K, Murakoshi N, Iemitsu M, et al. (2006) Doxorubicin induces apoptosis by activation of caspase-3 in cultured cardiomyocytes in vitro and rat cardiac ventricles in vivo. J Pharmacol Sci 101: 151-158.
6. Takemura G, Fujiwara H, (2007) Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49: 330-352.
7. Chatterjee K, Zhang J, Honbo N, Karliner JS, (2010) Doxorubicin cardiomyopathy. Cardiology 115: 155-162.
8. Kenk M, Thackeray JT, Thorn SL, Dhami K, Chow BJ, et al. (2010) Alterations of pre- and postsynaptic noradrenergic signaling in a rat model of adriamycin-induced cardiotoxicity. J Nucl Cardiol 17: 254-263.
9. Bernstein D, Fajardo G, Zhao M, Urashima T, Powers J, et al. (2005) Differential cardioprotective/cardiotoxic effects mediated by beta-adrenergic receptor subtypes. Am J Physiol Heart Circ Physiol 289: H2441-2449.
10. Fajardo G, Zhao M, Powers J, Bernstein D, (2006) Differential cardiotoxic/cardioprotective effects of beta-adrenergic receptor subtypes in myocytes and fibroblasts in doxorubicin cardiomyopathy. J Mol Cell Cardiol 40: 375-383.
11. Sun J, Fu L, Tang X, Han Y, Ma D, et al. (2011) Testosterone modulation of cardiac beta-adrenergic signals in a rat model of heart failure. Gen Comp Endocrinol 172: 518-525.
12. Dery AS, Hamilton LA, Starr JA, (2011) Nebivolol for the treatment of heart failure. Am J Health Syst Pharm 68: 879-886.
13. Rozec B, Erfanian M, Laurent K, Trochu JN, Gauthier C, (2009) Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart. J Am Coll Cardiol 53: 1532-1538.
14. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, et al. (2006) Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 48: 2258-2262.
15. Georgakopoulos P, Roussou P, Matsakas E, Karavidas A, Anagnostopoulos N, et al. (2010) Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. Am J Hematol 85: 894-896.
16. Senba M, Buziba N, Mori N, Morimoto K, Nakamura T, (2011) Increased prevalence of Kaposis sarcoma-associated herpesvirus in the Kaposis sarcoma-endemic area of western Kenya in 1981-2000. Acta Virol 55: 161-164.
17. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, et al. (2010) Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 55: 213-220.
18. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, et al. (1989) Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2: 358-367.
19. Liu J, Rigel DF, (2009) Echocardiographic examination in rats and mice. Methods Mol Biol 573: 139-155.
20. Mulvagh S, Quinones MA, Kleiman NS, Cheirif J, Zoghbi WA, (1992) Estimation of left ventricular end-diastolic pressure from Doppler transmitral flow velocity in cardiac patients independent of systolic performance. J Am Coll Cardiol 20: 112-119.
21. Popovic ZB, Benejam C, Bian J, Mal N, Drinko J, et al. (2007) Speckle-tracking echocardiography correctly identifies segmental left ventricular dysfunction induced by scarring in a rat model of myocardial infarction. Am J Physiol Heart Circ Physiol 292: H2809-2816.
22. Rautureau Y, Toumaniantz G, Serpillon S, Jourdon P, Trochu JN, et al. (2002) Beta 3-adrenoceptor in rat aorta: molecular and biochemical characterization and signalling pathway. Br J Pharmacol 137: 153-161.
23. Bian JS, Zhang WM, Xia Q, Wong TM, (1998) Phospholipase C inhibitors attenuate arrhythmias induced by kappa-receptor stimulation in the isolated rat heart. J Mol Cell Cardiol 30: 2103-2110.
24. Lou H, Danelisen I, Singal PK, (2004) Cytokines are not upregulated in adriamycin-induced cardiomyopathy and heart failure. J Mol Cell Cardiol 36: 683-690.
25. Tong J, Ganguly PK, Singal PK, (1991) Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats. Am J Physiol 260: H909-916.
26. Ghibu S, Delemasure S, Richard C, Guilland JC, Martin L, et al. (2012) General oxidative stress during doxorubicin-induced cardiotoxicity in rats: absence of cardioprotection and low antioxidant efficiency of alpha-lipoic acid. Biochimie 94: 932-939.
27. Iliskovic N, Singal PK, (1997) Lipid lowering: an important factor in preventing adriamycin-induced heart failure. Am J Pathol 150: 727-734.
28. Morishima I, Matsui H, Mukawa H, Hayashi K, Toki Y, et al. (1998) Melatonin, a pineal hormone with antioxidant property, protects against adriamycin cardiomyopathy in rats. Life Sci 63: 511-521.
29. Danelisen I, Palace V, Lou H, Singal PK, (2002) Maintenance of myocardial levels of vitamin A in heart failure due to adriamycin. J Mol Cell Cardiol 34: 789-795.
30. Iliskovic N, Panagia V, Slezak J, Kumar D, Li T, et al. (1997) Adriamycin depresses in vivo and in vitro phosphatidylethanolamine N-methylation in rat heart sarcolemma. Mol Cell Biochem 176: 235-240.
31. Nagy AC, Cserep Z, Tolnay E, Nagykalnai T, Forster T, (2008) Early diagnosis of chemotherapy-induced cardiomyopathy: a prospective tissue Doppler imaging study. Pathol Oncol Res 14: 69-77.
32. Stoddard MF, Seeger J, Liddell NE, Hadley TJ, Sullivan DM, et al. (1992) Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol 20: 62-69.
33. Tassan-Mangina S, Codorean D, Metivier M, Costa B, Himberlin C, et al. (2006) Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. Eur J Echocardiogr 7: 141-146.
34. Ho E, Brown A, Barrett P, Morgan RB, King G, et al. (2010) Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study. Heart 96: 701-707.
35. Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, et al. (2005) Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 23: 2629-2636.
36. Brouwer CA, Gietema JA, van den Berg MP, Bink-Boelkens MT, Elzenga NJ, et al. (2006) Long-term cardiac follow-up in survivors of a malignant bone tumour. Ann Oncol 17: 1586-1591.
37. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML, (1991) Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266: 1672-1677.
38. Kishida T, Muto S, Hayashi M, Tsutsui M, Tanaka S, et al. (2008) Strain differences in hepatic cytochrome P450 1A and 3A expression between Sprague-Dawley and Wistar rats. J Toxicol Sci 33: 447-457.
39. Jamesdaniel S, Ding D, Kermany MH, Jiang H, Salvi R, et al. (2009) Analysis of cochlear protein profiles of Wistar, Sprague-Dawley, and Fischer 344 rats with normal hearing function. J Proteome Res 8: 3520-3528.
40. Dhein S, Garbade J, Rouabah D, Abraham G, Ungemach FR, et al. (2006) Effects of autologous bone marrow stem cell transplantation on beta-adrenoceptor density and electrical activation pattern in a rabbit model of non-ischemic heart failure. J Cardiothorac Surg 1: 17.
41. Calderone A, de Champlain J, Rouleau JL, (1991) Adriamycin-induced changes to the myocardial beta-adrenergic system in the rabbit. J Mol Cell Cardiol 23: 333-342.
42. Nagami K, Yoshikawa T, Suzuki M, Wainai Y, Anzai T, et al. (1997) Abnormal beta-adrenergic transmembrane signaling in rabbits with adriamycin-induced cardiomyopathy. Jpn Circ J 61: 249-255.
43. Fu LX, Bergh CH, Hoebeke J, Liang QM, Sjogren KG, et al. (1991) Effect of metoprolol on activity of beta-adrenoceptor coupled to guanine nucleotide binding regulatory proteins in adriamycin-induced cardiotoxicity. Basic Res Cardiol 86: 117-126.
44. Nikolaev VO, Bunemann M, Schmitteckert E, Lohse MJ, Engelhardt S, (2006) Cyclic AMP imaging in adult cardiac myocytes reveals far-reaching beta1-adrenergic but locally confined beta2-adrenergic receptor-mediated signaling. Circ Res 99: 1084-1091.
45. Pavoine C, Defer N, (2005) The cardiac beta2-adrenergic signalling a new role for the cPLA2. Cell Signal 17: 141-152.
46. Xiao RP, Zhu W, Zheng M, Cao C, Zhang Y, et al. (2006) Subtype-specific alpha1- and beta-adrenoceptor signaling in the heart. Trends Pharmacol Sci 27: 330-337.
47. Zhu WZ, Zheng M, Koch WJ, Lefkowitz RJ, Kobilka BK, et al. (2001) Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci U S A 98: 1607-1612.
48. DeGeorge BR Jr, Gao E, Boucher M, Vinge LE, Martini JS, et al. (2008) Targeted inhibition of cardiomyocyte Gi signaling enhances susceptibility to apoptotic cell death in response to ischemic stress. Circulation 117: 1378-1387.
49. Ahmet I, Krawczyk M, Heller P, Moon C, Lakatta EG, et al. (2004) Beneficial effects of chronic pharmacological manipulation of beta-adrenoreceptor subtype signaling in rodent dilated ischemic cardiomyopathy. Circulation 110: 1083-1090.
50. Ahmet I, Krawczyk M, Zhu W, Woo AY, Morrell C, et al. (2008) Cardioprotective and survival benefits of long-term combined therapy with beta2 adrenoreceptor (AR) agonist and beta1 AR blocker in dilated cardiomyopathy postmyocardial infarction. J Pharmacol Exp Ther 325: 491-499.
51. Ahmet I, Morrell C, Lakatta EG, Talan MI, (2009) Therapeutic efficacy of a combination of a beta1-adrenoreceptor (AR) blocker and beta2-AR agonist in a rat model of postmyocardial infarction dilated heart failure exceeds that of a beta1-AR blocker plus angiotensin-converting enzyme inhibitor. J Pharmacol Exp Ther 331: 178-185.
52. Chakir K, Daya SK, Aiba T, Tunin RS, Dimaano VL, et al. (2009) Mechanisms of enhanced beta-adrenergic reserve from cardiac resynchronization therapy. Circulation 119: 1231-1240.
53. Chakir K, Depry C, Dimaano VL, Zhu WZ, Vanderheyden M, et al. (2011) Galphas-biased beta2-adrenergic receptor signaling from restoring synchronous contraction in the failing heart. Sci Transl Med 3: 100ra188.
54. Zhu W, Petrashevskaya N, Ren S, Zhao A, Chakir K, et al. (2012) Gi-biased beta2AR signaling links GRK2 upregulation to heart failure. Circ Res 110: 265-274.
55. Kaya MG, Ozkan M, Gunebakmaz O, Akkaya H, Kaya EG, et al. (2012) Protective effects of nebivolol against anthracycline-induced cardiomyopathy: A randomized control study. Int J Cardiol.